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Abstract 22 
Purpose: Although L-type Ca2+ channels are known to play a key role in the 23 
myogenic reactivity of retinal arterial vessels, the involvement of other types of 24 
voltage-gated Ca2+ channels in this process remains unknown. In the present study 25 
we have investigated the contribution of T-type Ca2+ channels to myogenic signalling 26 
in arterioles of the rat retinal microcirculation.  27 
Methods: Confocal immunolabelling of wholemount preparations was used to 28 
investigate the localisation of CaV3.1–3 channels in retinal arteriolar smooth muscle 29 
cells. T-type currents and the contribution of T-type channels to myogenic signalling 30 
were assessed by whole-cell patch-clamp recording and pressure myography of 31 
isolated retinal arteriole segments.  32 
Results: Strong immunolabelling for CaV3.1 was observed on the plasma membrane 33 
of retinal arteriolar smooth muscle cells. In contrast, no expression of CaV3.2 or 34 
CaV3.3 could be detected in retinal arterioles, although these channels were present 35 
on glial cell end-feet surrounding the vessels and retinal ganglion cells, respectively. 36 
TTA-A2-sensitive T-type currents were recorded in retinal arteriolar myocytes with 37 
biophysical properties distinct from those of the L-type currents present in these 38 
cells. Inhibition of T-type channels using TTA-A2 or ML-218 dilated isolated, 39 
myogenically active, retinal arterioles.  40 
Conclusions: CaV3.1 T-type Ca2+ channels are functionally expressed on arteriolar 41 
smooth muscle cells of retinal arterioles and play an important role in myogenic 42 
signalling in these vessels. The work has important implications concerning our 43 
understanding of the mechanisms controlling blood flow autoregulation in the retina 44 
and its disruption during ocular disease.  45 
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Introduction 46 
It has long been known that alterations in perfusion pressure generate compensatory 47 
changes in the diameters of retinal vessels that result in minor or no effects on 48 
overall retinal blood flow.1 A reduced ability of the retina to autoregulate in this 49 
manner has been associated with a number of ocular diseases including diabetes, 50 
glaucoma and age-related macular degeneration (AMD).2–6 Vascular autoregulation 51 
in the retina is driven by a number of different mechanisms, with both myogenic and 52 
metabolic components involved.7 The importance of myogenic mechanisms in the 53 
regulation of retinal blood flow has been highlighted by several studies performed on 54 
isolated retinal arteries and arterioles, showing vasoconstriction or vasodilation in 55 
response to either increases or decreases in intravascular pressure, respectively.8–11  56 
 According to the classical view, myogenic responses occur when 57 
pressure-induced distension of the vessel wall triggers activation of stretch-activated 58 
cation channels on the resident vascular smooth muscle cells, resulting in cell 59 
membrane potential depolarisation and increased Ca2+ influx through 60 
voltage-operated L-type Ca2+ channels.12–14 This Ca2+ influx in turn leads to vascular 61 
smooth muscle cell contraction and vessel constriction both directly by increasing the 62 
cytosolic Ca2+ concentration and indirectly by triggering the release of Ca2+ from the 63 
sarcoplasmic reticulum via ryanodine (RyR) and inositol trisphosphate receptor 64 
channels.12–14 We have previously shown that L-type Ca2+ channels and RyR 65 
receptors play a key role in myogenic signalling in retinal arterioles.10,11 These 66 
vessels also express voltage-gated Kv1.5 channels11,15 and large-conductance Ca2+-67 
activated K+ channels (BK channels)11,16 which act as a brake on the myogenic 68 
response mechanism by limiting the degree of pressure-induced depolarisation. 69 
Ca2+-activated Cl- channels have also been found to contribute to the contractile 70 
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state of these vessels, although their primary role appears to be in the modulation of 71 
agonist-induced tone, rather than myogenic signalling.17,18  72 
 Recent studies in other vascular beds have suggested that additional ion 73 
channels, such as T-type Ca2+ channels, might function as alternative 74 
voltage-dependent Ca2+ influx pathways that may be involved in the development 75 
and maintenance of myogenic tone.19,20 Molecular analyses have identified three 76 
different isoforms of pore-forming T-type Ca2+ channels, namely CaV3.1, CaV3.2 and 77 
CaV3.3.21,22 Several studies have found some of these to be expressed and 78 
functional in resistance vessels,23–25 contributing in some cases to myogenic 79 
signalling.20,23,26–28 T-type Ca2+ channels appear to be particularly important in 80 
mediating myogenic responses in small arterioles where, despite a loss or decrease 81 
in L-type Ca2+ currents, development of myogenic tone is still observed.26,29,30 82 
 In the present study, we have investigated for the first time the possible 83 
involvement of T-type Ca2+ channels in the myogenic reactivity of rat retinal 84 
arterioles. Using immunohistochemistry, we show that although all three T-type Ca2+ 85 
channel isoforms are expressed in retinal tissue, only CaV3.1 localises to retinal 86 
arteriolar smooth muscle cells. We also demonstrate the functional expression of T-87 
type Ca2+ channels on the plasma membrane of these cells and characterise their 88 
biophysical and pharmacological properties. Finally, we show that two structurally 89 
distinct T-type Ca2+ channel blockers dilate isolated pressurised retinal arterioles 90 
under conditions of steady state myogenic tone, suggesting that these channels 91 
make a significant contribution to myogenic signalling in these vessels. These 92 
findings have important implications for our understanding of the mechanisms 93 
controlling retinal blood flow in both health and disease.             94 
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Methods 95 
Animal use conformed to the standards in the ARVO Statement for the Use of 96 
Animals in Ophthalmic and Vision Research. Male Sprague-Dawley rats (8–12 97 
weeks of age; 200–250g; Harlan, Bicester, UK) were euthanized with CO2 in 98 
accordance with guidelines contained within the UK Animals (Scientific Procedures) 99 
Act of 1986 and approved by the Queen’s University of Belfast Animal Welfare and 100 
Ethical Review Body.  101 
 102 
Immunohistochemistry 103 
Immunohistochemistry was carried out on retinal arterioles embedded within retinal 104 
flatmount preparations as described previously.16 Briefly, freshly enucleated eyes 105 
were placed in low Ca2+ Hanks solution (see Drugs and Solutions) and hemisected 106 
along the ora serrata. The vitreous was removed and the posterior eyecup fixed with 107 
4% paraformaldehyde (PFA) for 20 minutes and then washed extensively in 108 
phosphate buffered saline (PBS) for 1 hour. Retinas were subsequently detached 109 
and incubated overnight in permeabilisation and blocking buffer (0.05% Triton X-100 110 
and 1% donkey serum in PBS; Sigma, Poole, Dorset, UK, and Millipore, Watford, 111 
UK) and then incubated in primary antibody in permeabilisation and blocking buffer 112 
for 3 days at 4°C. Primary antibodies, selected on the basis of their specificity 113 
towards rat CaV3.1–3 channels (Table 1) were employed in conjunction with mouse 114 
anti--smooth muscle actin (αSMA) antibody (1:200; Sigma) to positively identify 115 
vascular smooth muscle cells or isolectin B4 (1:50; Sigma)31 to label vascular plasma 116 
membranes. Following extensive washing (4 hours at 21°C in PBS), donkey anti-117 
rabbit IgG labelled with Alexa-488 (Life Technologies, Paisley UK; 1:200 in 118 
permeabilisation and blocking buffer) or Streptavidin 568 (Life Technologies; 1:500) 119 
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were used for CaV3.1–3 channel and vascular cell membrane detection, respectively 120 
(incubated 4°C overnight). The αSMA primary antibody was conjugated to Cy3, so 121 
no secondary antibody was required. Nuclei were labelled with the far-red nuclear 122 
stain TOPRO3 (1:1000; Life Technologies; pseudo-coloured blue in relevant 123 
images). The immunohistochemistry for each of the CaV3.1–3 isoforms was repeated 124 
using 4–8 retinas from at least 4 different animals. Secondary only controls and 125 
blocking peptide experiments for CaV3.1 (10g/ml blocking peptide) were also 126 
performed. Images were acquired using a Leica SP5 confocal laser scanning 127 
microscope (Leica Geosystems; Heerbrugg, Switzerland; HCX PL APO 63x OIL 128 
immersion lens) equipped with Argon, HeNe 543 and HeNe 633 lasers. Images were 129 
captured in sequential scanning mode with emission wavelengths appropriate for the 130 
fluorophores used to reduce overlap (bleed-through) of signals.  131 
 132 
Isolated Arteriolar Preparation 133 
For electrophysiology and pressure myography experiments, isolated retinal arteriole 134 
segments were used.32 Retinas were dissected from freshly enucleated eyes, placed 135 
in low Ca2+ Hanks’ solution and mechanically triturated using a fire-polished Pasteur 136 
pipette. Homogenate was pipetted into a glass-bottomed recording bath mounted on 137 
an inverted microscope (Eclipse TE300; Nikon, Tokyo, Japan) and isolated retinal 138 
arterioles (length, 100–4000 μm; outer diameter, 15–40 μm) anchored down with 139 
tungsten wire slips as described previously.16 Arterioles were continuously 140 
superfused with normal Hanks’ solution at 37°C during experimentation. Drugs were 141 
delivered via a gravity-fed multi-channel perfusion manifold connected to a single 142 
outlet needle that was positioned adjacent to the vessel of interest. 143 
 144 
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Electrophysiological Recordings 145 
Whole-cell membrane currents were recorded from individual arteriolar smooth 146 
muscle cells still embedded within their parental arterioles using the perforated 147 
patch-clamp technique.33 Prior to patching, the vessels were superfused with 148 
collagenase 1A (0.1 mg/ml, 10 minutes; Sigma), protease type XIV (0.01 mg/ml, 10 149 
minutes; Sigma) and DNAse I (0.02 mg/ml, 5 minutes; Millipore) in low Ca2+ Hanks’ 150 
solution to remove surface basal lamina, electrically uncouple endothelial cells from 151 
overlying arteriolar smooth muscle cells and individual smooth muscle cells from one 152 
another, and to remove extraneous DNA.15,33 Once the whole-cell perforated 153 
configuration was acquired, the external Hanks' solution was switched to divalent 154 
free solution (see Drugs and Solutions) to enhance the magnitude of currents flowing 155 
through voltage-gated Ca2+ channels and to prevent interference by Ca2+-activated 156 
Cl- currents.34,35 Pipettes pulled from filamented borosilicate glass capillaries (1.5 157 
mm o.d. w 1.17 mm i.d., Harvard Instruments, Kent, UK) were fire polished to 158 
resistances of 1-2 MΩ. Membrane currents were recorded using an Axopatch 200B 159 
patch-clamp amplifier (Molecular Devices, CA, USA), low pass filtered at 0.5 kHz 160 
and sampled at 2 kHz. Voltage step protocols were applied using pClamp (version 161 
10.2; Molecular Devices) via a Digidata 1440A interface (Molecular Devices). Leak 162 
currents were subtracted off-line from the active currents using the response to a 163 
hyperpolarizing step from a holding potential of –80 mV to –90 mV as the correction 164 
signal. Calculation and plotting of difference curves, off-line leak subtraction and 165 
fitting of exponentials was performed using purpose-written software in R.36  166 
Arteriolar Myography 167 
The involvement of T-type Ca2+ channels in the generation of arteriolar myogenic 168 
tone was assessed using pressure myography as previously described.16 A tungsten 169 
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wire slip was laid on the arteriole, anchoring and occluding one end. The vessel was 170 
then superfused with Ca2+-free Hanks’ solution. The open end was cannulated using 171 
a glass micropipette (1.5mm o.d., 0.86 i.d. tapered to a tip diameter of 2–5 μm) filled 172 
with Ca2+-free Hanks’ solution, using a patch-clamp electrode holder and 173 
micromanipulator (Molecular Devices).  Once the pipette tip had been appropriately 174 
positioned, the pipette was advanced so as to wedge it tightly into the lumen of the 175 
vessel. To ensure there was no significant flow through the vessel or leakage of fluid 176 
around the cannulation site, a small air bubble was introduced into the tubing 177 
connecting the cannulating pipette to the manometer. Only vessels where this 178 
bubble remained relatively static following pressurisation were used for 179 
experimentation. Following introduction of the pipette, the vessel was superfused 180 
with normal Hanks’ solution for 10–15 minutes, allowing the pipette to seal to the 181 
inner vessel wall. Vessels were then pressurised to 40 mmHg and left at that 182 
pressure until stable myogenic tone had fully developed (usually 10 minutes). 183 
Intraluminal pressure was regulated by using a manometer connected to the 184 
cannulating micropipette (Riester "Big Ben" pressure manometer; Riester, 185 
Jungingen, Germany). The maximum passive diameter of the vessels was 186 
determined by application of the myosin light chain kinase inhibitor, wortmannin (10 187 
μM),37,38 in the presence of Ca2+-free Hanks’ solution at the end of the experiment. 188 
This value was used to normalise vessel diameter data across individual arterioles. 189 
Vessels were viewed under a 20x, NA 0.4 objective and images (saved as BMP 190 
images of 1280x1024 pixels; 8-bit; 1.2MB) captured at a rate of 140 images per 191 
minute using a MCN-B013-U USB camera (Mightex, Pleasanton, CA, USA). 192 
Acquisition was carried out using custom software implemented in Delphi.16 The 193 
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measurement of vessel diameters and tracking of diameter changes was performed 194 
using the MyoTracker software package.39  195 
 196 
Drugs and Solutions 197 
The composition of the solutions used was as follows (in mM): Normal Hanks’ 198 
solution - 140, NaCl; 6, KCl; 5, D-glucose; 2, CaCl2; 1.3, MgCl2; 10, HEPES; pH set 199 
to 7.4 with NaOH; Divalent free solution - 120, NaCl; 5, KCl; 5, D-glucose; 10, 200 
HEPES; 5, EGTA; 20, Tetraethylammonium Chloride (TEA); K+-based internal 201 
pipette solution; 52, KCl; 80, Gluconic acid; 80, KOH; 1, MgCl2; 0.5, EGTA; 10, 202 
HEPES; pH set to 7.2 with KOH. The low Ca2+ Hanks’ solution was of Hanks’ 203 
composition, but contained only 0.1 mM Ca2+. For the Ca2+ free Hanks’ solution, 204 
Ca2+ was omitted. Amphotericin B (final concentration of 0.39 mM) was dissolved in 205 
the pipette solutions as the pore-forming agent.   206 
Unless otherwise stated, stock solutions of drugs were initially prepared in 207 
DMSO and then diluted to the final concentration. The final bath concentration of 208 
DMSO was ≤0.1%. In vehicle control experiments, application of DMSO, at the 209 
maximal concentration used in these studies, had no effect on arteriolar diameter 210 
(Table 2). Amphotericin B, nimodipine, TEA and EGTA were obtained from Sigma; 211 
TTA-A2, ML-218 and wortmannin were purchased from Alomone Labs (Jerusalem, 212 
Israel). HEPES was obtained from Melford Laboratories (Ipswich, UK). 213 
 214 
Statistical Analysis 215 
Data are presented as the mean ± SEM. Statistical significance was determined by 216 
using either paired t-tests (when data conformed to Kolmogorov-Smirnov normality 217 
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tests) or the Wilcoxon matched-pairs signed rank test for which no assumptions 218 
about normality were made. In all comparisons, the 95% level was accepted as 219 
statistically significant. Analysis was carried out using Prism 5 for Windows (version 220 
5.03; GraphPad Software Inc., La Jolla, CA, USA). In all graphical representations of 221 
the data, statistical significance is indicated as follows: NS, P>0.05; *=P<0.05; 222 
**=P<0.01; ***=P<0.001. 223 
  224 
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Results 225 
Immunolocalisation of T-Type Ca2+ Channels in Retinal Arteriolar Smooth 226 
Muscle  227 
The expression of the three T-type channel isoforms, CaV3.1, CaV3.2 and CaV3.3, 228 
was examined in rat retinal wholemount preparations using immunohistochemistry. 229 
Retinal arterioles were identified by positive staining for αSMA with a single 230 
monolayer of vascular smooth muscle cells running transversely to the long axis of 231 
the vessels (Fig. 1 A). In contrast, venules showed much weaker αSMA staining of 232 
pericyte-like mural cells (Fig. 1 B). As shown in Figure 2, strong immunolabelling for 233 
CaV3.1 proteins was detected on the surface of the retinal arteriolar smooth muscle 234 
cells, along with weaker, more diffuse, cytosolic staining (Fig. 2 A). Plasma 235 
membrane expression of CaV3.1 channels was confirmed by co-localisation with 236 
isolectin B4 (Fig. 2 B). In the surrounding retinal neuropile, CaV3.1 expression was 237 
also localised to retinal ganglion cells (RGCs; Fig. 2 A). Control experiments 238 
performed with secondary antibodies only or primary anti-CaV3.1 antibodies 239 
pre-absorbed with a specific blocking peptide were negative (Fig. 2 C). Expression of 240 
CaV3.2 was detected in close proximity to the retinal arterioles (Fig. 2 D). However, 241 
on closer inspection, it was evident that this expression was limited to the 242 
perivascular end-feet of glial cells surrounding the vessels. CaV3.3 expression was 243 
absent from retinal arterioles, but strong immunolabelling was present in the 244 
surrounding retinal neuropile primarily associated with RGCs (Fig. 2 E).  245 
 246 
 247 
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Electrical Characterisation of the T-Type Currents 248 
Whole-cell patch-clamp experiments were conducted to examine the functional 249 
expression of T-type Ca2+ channels on the plasma membrane of retinal arteriolar 250 
smooth muscle cells. Figure 3 shows voltage-dependent inward T-type currents 251 
sensitive to external application of the selective T-type Ca2+ channel inhibitor, TTA-252 
A2 (1 μM; Fig. 3 A, left panel),40,41 and L-type currents sensitive to nimodipine (1 μM; 253 
Fig. 3 A, right panel)10. Representative and average current-voltage (I-V) 254 
relationships for both TTA-A2- and nimodipine-sensitive currents are also shown 255 
(Fig. 3 B, left and right panels, respectively). As can be seen, the TTA-A2-sensitive 256 
I-V curve activates at a more negative membrane potential than the 257 
nimodipine-sensitive current (–70 mV for the T-type current compared to –50 mV for 258 
the L-type current; Fig. 3 B). This is also the case for the peak currents, with T-type 259 
current peaking at around –30 to –20 mV, compared to –10 to 0 mV for the L-type 260 
current (Fig. 3 B). These currents also displayed significant differences in their rates 261 
of activation and inactivation, with the T-type currents having a faster rate of both 262 
activation (Tac 4.3 ± 0.7 versus 8.2 ± 1.3 ms) and inactivation (Tinac 18.2 ± 1 versus 263 
24.1 ± 1.5 ms) compared with the L-type currents (P<0.01 in both cases, n=8; Fig. 3 264 
C and D). Thus, these results confirm that T-type Ca2+ channels are functionally 265 
expressed in retinal arteriolar smooth muscle cells, and in the final experiments, 266 
analyses were performed to examine their possible role in the myogenic reactivity of 267 
retinal arterioles. 268 
 269 
 270 
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Blocking T-Type Ca2+ Channels Causes Dilation of Pressurised Retinal 271 
Arterioles 272 
To investigate the possible role of T-type channels in myogenic signalling, we carried 273 
out pressure myography experiments on isolated retinal arterioles. Vessels were 274 
cannulated and pressurised to 40 mmHg until myogenic tone had fully developed 275 
and stabilised. Arterioles were then exposed to TTA-A2 (1 μM) or another selective 276 
T-type Ca2+ channel blocker, ML-218 (1 μM),42 and changes in vessel diameter 277 
recorded. At the end of the experiment, wortmannin (10 μM), was applied in Ca2+-278 
free Hanks' solution in order to obtain the maximal passive diameter of the vessels. 279 
Both TTA-A2 and ML-218 caused a significant dilation of myogenically active rat 280 
retinal arterioles by 50% of the maximal passive diameter (P<0.001, Wilcoxon 281 
matched-pairs signed rank test; Fig. 4 A and B, Table 2). These findings are 282 
consistent with the view that T-type Ca2+ channels contribute to the generation of 283 
myogenic tone in these vessels. 284 
 285 
  286 
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Discussion 287 
This study shows for the first time that the T-type Ca2+ channel isoform, CaV3.1, is 288 
functionally expressed in vascular smooth muscle cells of rat retinal arterioles and 289 
plays an important role in myogenic signalling in these vessels. Although we found 290 
no evidence for expression of CaV3.2 or CaV3.3 channels in these vessels, these 291 
isoforms were identified in glial cell end-feet surrounding the vessels (CaV3.2; Fig. 2 292 
D) and RGCs (CaV3.3; Fig. 2 E). Our results are consistent with previous studies 293 
reporting CaV3.1 expression in vascular smooth muscle cells of other vascular beds, 294 
including those of the renal, skeletal muscle, mesenteric, brain and pulmonary 295 
circulations.23,24,27,30,43–45 Although expression of CaV3.3 has not been widely 296 
reported in vascular smooth muscle cells, CaV3.2 has been detected in cerebral and 297 
pulmonary artery myocytes.20,45 Recent work has established that Ca2+ influx through 298 
vascular smooth muscle CaV3.2 channels is principally involved in mediating 299 
vasodilatory responses via activation of RyR-dependent Ca2+ sparks and BK 300 
channels.28 It would appear unlikely, however, that such a mechanism is active in 301 
retinal arterioles, given that CaV3.2 channels could not be detected in these vessels.  302 
 Consistent with the presence of CaV3.1 channels on the plasma membrane of 303 
retinal arteriolar myocytes, we identified T-type currents with pharmacological and 304 
kinetic features similar to those produced by CaV3.1 subunits in other systems (Fig. 305 
3).21,46 These currents were different from the L-type voltage-dependent Ca2+ 306 
currents in these cells in that they were activated at lower membrane potentials and 307 
had faster kinetic rates of activation and inactivation (Fig. 3). Similar kinetic rates 308 
have been reported for T-type channels in other vascular tissues.21,28,47 Some 309 
studies carried out on mesenteric and cerebral arteries, however, have reported an 310 
unexpected depolarising shift in the activation and inactivation profiles of these 311 
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channels compared to traditional T-type channels, leading to the suggestion that in 312 
vascular myocytes the T-type channels may be formed from splice variants.48 In our 313 
study, however, we could detect two clearly distinguishable peaks in the I-V curves 314 
for T-type and L-type currents, closer to traditional T-type values, and the peak  I-V 315 
values shown here (–30 to –20 mV) closely match those reported for T-type currents 316 
in other cells, including neurons, cardiomyocytes and coronary and aortic vascular 317 
smooth muscle cells.21  318 
 Although L-type Ca2+ channels are generally believed to play a central role in 319 
the development of myogenic tone,13 it has been noted in several studies that L-type 320 
Ca2+ channel inhibition does not completely abolish the myogenic response.19,20,49–51 321 
In the present study, we have demonstrated that two different T-type blockers, 322 
TTA-A2 and ML-218, are capable of partially inhibiting myogenic signalling in 323 
isolated rat retinal arterioles (Fig. 4; Table 2). Whilst the absolute changes in vessel 324 
diameter that we have recorded following T-type Ca2+ channel blockade are 325 
relatively small, we have calculated for individual arterioles that these would be 326 
expected to decrease vascular resistance in the range of 3-15% (mean of 7%; 327 
based on R1/d4).10 Thus it seems likely that these channels will make at least some 328 
contribution to the modulation of retinal blood flow autoregulation in vivo. Our data 329 
concur with other studies showing that CaV3.1 T-type channels play an important 330 
role in the development and maintenance of myogenic tone in vessels from several 331 
vascular beds. Navarro-Gonzalez et al. (2009), for example, showed that myogenic 332 
tone in the rat basilar artery results from Ca2+ influx through nifedipine-insensitive 333 
voltage-dependent Ca2+ channels with characteristics similar to the T-type channel 334 
isoform CaV3.1.43 Björling et al. (2013), working with mice deficient in the CaV3.1 T-335 
type isoform, showed that T-type channels are crucial for myogenic tone in 336 
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mesenteric arteries at low arterial pressure (<80 mmHg), but are inactivated at high 337 
arterial pressure where L-type Ca2+ channels predominate in the myogenic 338 
response.20,52–54 Since the arterial input pressure in the retina is thought to be 40 339 
mmHg,55,56 and retinal arterioles exhibit myogenic tone between 10 and 70 340 
mmHg,9,10,57 these observations would support the view that CaV3.1 T-type channels 341 
are likely to play an important role in both setting basal vascular tone and in 342 
modulating vascular tone in response to changes in systemic blood pressure (i.e. in 343 
mediating blood flow autoregulation) in the retinal microcirculation in vivo.   344 
 In summary, this study is the first to identify CaV3.1 T-type currents in vascular 345 
smooth muscle cells of retinal arterioles and to characterise their contribution to 346 
myogenic signalling in these vessels. The work provides an important foundation for 347 
better understanding the mechanisms regulating retinal perfusion in both health and 348 
disease. It seems likely, for example, that in addition to contributing to the myogenic 349 
reactivity of retinal arterioles, endothelial and glial cell mediators known to modulate 350 
retinal vascular tone and blood flow may, at least in part, act by targeting the activity 351 
of these channels. In support of this idea, previous studies have shown that 352 
vasodilator molecules such as nitric oxide and 5,6 epoxyeicosatrienoic acid are 353 
capable of inhibiting T-type Ca2+ channel activity,58,59 while the vasoconstrictor 354 
peptide, endothelin-1, has been shown to enhance currents through these 355 
channels.60 From a pathophysiological perspective, we currently have only a limited 356 
knowledge of the role of T-type Ca2+ currents in the development of vascular 357 
disease, although CaV3.1 channels have been identified as potential therapeutic 358 
targets for the prevention of restenosis following angioplasty.61 Our current work 359 
opens up several new avenues for further research. The possibility that alterations in 360 
CaV3.1 channel expression and activity contribute to the loss of retinal vascular 361 
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autoregulation and blood flow disturbances during diseases such as diabetes, 362 
glaucoma and AMD now merits further investigation.  363 
 364 
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Figure legends 553 
Figure 1. (A) Arteriole and (B) venule within a retinal wholemount preparation 554 
immunolabelled for α-SMA (red channel). Nuclei were labelled with the far-red 555 
nuclear stain TOPRO3 (pseudo-coloured blue). 556 
Figure 2. Distribution patterns of CaV3.1-3 T-type channel isoforms in retinal 557 
arterioles and the surrounding retinal parenchyma (A) Top panel, rat retinal 558 
wholemount preparation immunolabelled for CaV3.1 (green channel), αSMA (red 559 
channel) and cell nuclei (blue channel; TOPRO3). Bottom panel, CaV3.1 staining 560 
segmented from the same image. (B) Individual and merged images showing CaV3.1 561 
(green channel) co-localisation with the plasma membrane marker, isolectin B4 (red 562 
channel), in retinal arteriolar myocytes. (C) Top panel, secondary only control image. 563 
Bottom panel, blocking peptide experiment for the anti-CaV3.1 primary antibody. (D, 564 
E) Equivalent immunolabelling to that shown in A, but for CaV3.2 and CaV3.3 565 
isoforms, respectively.  566 
Figure 3. (A) TTA-A2-sensitive T-type currents (left panel) and nimodipine-sensitive 567 
L-type currents (right panel) elicited in response to voltage steps from -80 to +40mV 568 
in 10 mV increments from a holding potential of -80 mV. Current traces are 569 
presented as difference currents. (B) Representative (left) and mean (right) I-V 570 
relationships (n=8 cells) for the TTA-A2 and nimodipine-sensitive currents. (C) 571 
Kinetic rate constants of activation and inactivation for the currents obtained in A. 572 
Analysis was carried out on currents obtained at a voltage step to –10 mV (left 573 
panel). Dashed boxes indicate both the activation (magnified in the middle panel) 574 
and inactivation (magnified in the right panel) of the currents at that voltage. 575 
23 
 
Activating and inactivating currents were fitted using single exponentials. (D) Mean 576 
time constants of activation (left) and inactivation (right) (n=8). 577 
Figure 4. Effects of T-type blockers on the diameter of isolated retinal arterioles 578 
under myogenic tone. (A) Representative traces showing the diameters of vessels 579 
under steady-state myogenic tone (grey line, actual diameter;  black line, smoothed 580 
trace showing the moving average of 11 points superimposed on top of the raw 581 
diameters) at an intraluminal pressure of 40 mmHg (first 2–3 minutes), dilation of the 582 
vessel after application of the T-type blocker (TTA-A2, 1 μM, left panel; ML-218, 1 583 
μM, right panel), and subsequent further dilation to the maximal passive diameter 584 
after application of wortmannin in Ca2+-free Hanks' solution. (B) Mean arteriole 585 
diameters normalised to the maximal diameters following application of DMSO, TTA-586 
A2 or ML-218.  587 
 588 
Table 1. Antibodies and dilutions used to investigate CaV3.1–3 protein expression. 589 
Protein Antibody (Company) Epitope(species) Dilution 
CaV3.1 ACC-021 (Alomone; Jerusalem, 
Israel) 
AA1–22 (rat) 1:200 
CaV3.2 ACC-025 (Alomone) AA581–595 (human) 1:200 
CaV3.3 OSC00263W (Osenses; Keswick, 
Australia) 
AA450-500 (human) 1:200 
 590 
Table 2. Effects of T-type blockers on the diameters of pressurised retinal arterioles. 591 
Diameters 
(μm) 
After steady-state 
tone development 
In presence of 
vehicle/inhibitor 
Passive 
diameter 
% diameter 
change 
 
DMSO (n=10) 
 
29.5 ± 1.6  
 
29.4 ± 1.5  
 
30.6 ± 1.4  
 
N/A  
TTA-A2 (n=16) 29.1 ± 2.4  29.6 ± 2.5  30.1 ± 2.5  45.4 ± 3.9  
ML-218 (n=13) 
 
31.3 ± 2.7  31.8 ± 2.7  32.3 ± 2.7  54.1 ± 4.2  
 592 




